Samsung purchases genetics-focused telehealth business as coronavirus raves

Samsung’s Catalyst Fund is wagering the future of healthcare will have something to do with genomics — specifically as the world fights the coronavirus pandemic. The fund, which is supervised by Samsung Strategy Chief Young Sohn, has actually led a financial investment into the  San Francisco Bay Area-based Genome Medical, the business stated Wednesday. 

The Series B extension funding raised $14 million to assist Genome Medical broaden its genomics telehealth push. In overall, it has actually raised $60 million given that its starting in 2016. Other financiers consist of the endeavor arm of health center Kaiser Permanente, Canaan, Illumina Ventures and Echo Health Ventures. 

Genome Medical integrates telemedicine with genomics, with the goal to offer more tailored care to clients throughout the nation. Genomics includes studying an individual’s genes, along with the interaction of those genes with each other and with an individual’s environment, to identify how they affect an individual’s possibility to establish — and after that fight — conditions like cardiovascular disease and cancer. It likewise checks out how an individual will react to specific drugs based upon their genes, something called pharmacogenomics. 

It’s thought that genomics can develop brand-new methods to keep track of and deal with contagious illness like COVID-19. At the exact same time, getting care digitally takes pressure off of overloaded healthcare facilities and clinicians who are dealing with individuals ill with the coronavirus. About 10.5 million individuals have actually been contaminated up until now and more than 500,000 individuals have actually passed away. There’s no treatment or vaccine to avoid COVID-19 yet. 

“In general, medicine moves fairly slowly,” Lisa Alderson, CEO and co-founder of Genome Medical, stated in an interview prior to revealing the financial investment. But the coronavirus “has actually acted as a driver [to go virtual], out of requirement.”

Genome Medical links clients with hereditary specialists — and does it digitally. Patients get assistance over the phone or video talks on how hereditary screening works, what tests would be suitable and what the outcomes really suggest, along with get assist establishing a post-testing care strategy. The start-up prepares to utilize its brand-new financing to broaden its Genome Care Delivery innovation platform for cancer, reproductive health and pharmacogenomics screening.

About 10% of cancers are acquired, and about one out of every 4 people who go through reproductive hereditary screening are discovered to be providers of a hereditary condition, Genome Medical stated. Overall, about 17% of the United States population brings disease-related hereditary anomalies that can be dealt with or avoided. Increasingly, healthcare is using hereditary screening to identify treatment strategies. Doing so decreases expenses and enhances client results. 

One of the very best understood examples is evaluating for a BRCA gene anomaly that causes a greater danger for breast cancer. Many ladies who check favorable, like starlet Angelina Jolie, decide to have surgical treatment to avoid cancer from establishing in the future. 

“The future of healthcare delivery certainly has genetics and genomics as the cornerstone,” Alderson stated.  “The vast majority of patients, as part of routine medical care in the future, will receive some form of … genetic screening,”

An entire brand-new pandemic world

The coronavirus has actually altered a lot about routine life, from grocery shopping to getting hairstyles. One of the greatest locations that’s been affected is healthcare. Even prior to COVID-19 struck the world, individuals had actually begun visiting their medical professionals digitally. As individuals prevent going to healthcare facilities and medical professionals’ workplaces, that pattern has actually sped up. Now, we’re “visiting” our doctors on video calls and talking with medical bots to prevent seeing medical professionals face to face. 

In 2018, 7 million clients utilized some sort of a telemedicine service in the United States, which number is just anticipated to increase. Over half of United States healthcare facilities utilize some sort of telemedicine, and it remains in every state, with more than 200 telemedicine networks in the United States alone. In March, the United States Federal Communications Commission allocated $200 million to assist health companies present telehealth innovation to fight COVID-19. The FCC stated the services would be utilized to straight assist COVID-19 clients along with offer care to clients with other conditions who may be at danger of contracting the coronavirus if they needed to check out a healthcare supplier face to face. 

Coronavirus reopenings: How it looks as lockdowns relieve worldwide

See all images

Kaiser Permanente, among Genome Medical’s financiers, in mid-May stated about 80% of its client sees are now through some kind of telehealth, consisting of video sees. The healthcare supplier, which has a network of over 12.4 million clients, stated that pre-coronavirus, just 15% of its visits were telehealth. The rest were in-person workplace sees.

“Before, telehealth was a choice and convenience, but now it’s one of the ways patients remain healthy with social distancing,” Dr. Edward Lee, primary details officer of The Permanente Federation, stated in May. “Having both our physicians and patients go through the experience of providing and receiving care through telehealth has opened their eyes to the possibility of how the future will look.”

Genome Medical’s innovation offers clients access to over 50 hereditary specialists who they might not usually have the ability to fulfill, from MDs to hereditary therapists. Genome Medical’s hereditary professionals offer care in 6 locations: cancer, heart disease, reproductive health, pediatric genes, pharmacogenomics and proactive health management.  

The system makes it simple to buy tests and schedule specialist follow-up with individualized medical strategies. Part of Genome Medical’s service is to assist clients “navigate to the right expert,” Alderson stated. 

“That is tricky because genetics is super complex,” she stated. “There [are] a great deal of sub specializeds, and there are really couple of specialists in the nation.” There are just about 2,500 geneticists in the United States, she included. Most of those specialists have actually been based in leading scholastic centers like Stanford University, an area that’s not practical for individuals who might require hereditary therapy, especially at a time when much of the nation deals with stay-at-home orders.

Now playing:
Watch this:

Health care may never be the same. Mobile can help

28:44

Before the pandemic, patients who needed care from those genomics experts traveled to those centers, Alderson said. The wait times to see the specialists could be weeks or even months. Now, that travel is largely impossible. 

“We’re moving from this era where it was super-specialized knowledge and only the most extreme cases were referred to genetics into a world where it’s part of routine medical practice,” she said. 

Samsung investments

When Samsung launched its Catalyst Fund in 2013, it had a $100 million investment budget and a mandate to invest in early stage companies focused on components and subsystems. That included companies like Keyssa, which has developed a solid-state connector providing low-power, high-speed data transfer. But the Catalyst Fund’s investments have broadened beyond simply components to areas like artificial intelligence, cloud infrastructure, self-driving car tech, security and smart home tech. 

Genome Medical isn’t Samsung’s first health-related investment. The Catalyst Fund has invested in several other startups, including another genetics health-care company called Apton Biosystems. Apton has developed a fast, low-cost sequencing platform that aims to “revolutionize the availability and affordability of genetic analysis.”

Samsung declined to say how much it invested in Genome Medical. 

“Personalized medicine is the future of care, but too many health systems are not able to provide these critical services,” Francis Ho, senior vice president and managing director of the Samsung Catalyst Fund, said in a press release. “The data and knowledge base built by Genome Medical will spur more innovation and help us focus on preventive methods for treating illnesses and new diseases.”

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.